(R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine di-p-toluoyl-D-tartrate | 1228312-21-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine di-p-toluoyl-D-tartrate
• 英文别名: (2S,3S)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid;3-(oxan-4-yloxy)-5-[(E)-2-[(3R)-pyrrolidin-3-yl]ethenyl]pyridine
• CAS: 1228312-21-7
• 化学式: C₁₆H₂₂N₂O₂*C₂₀H₁₈O₈
• 分子量: 660.721
• InChiKey: WGKCRDINKKGVES-HAKSGUPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.49
• 重原子数：
  48
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  171
• 氢给体数：
  3
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydro-2H-pyran-4-yloxy)pyridine 、 D-(+)-二对甲基苯甲酰酒石酸 以 乙醇 为溶剂， 以72%的产率得到(R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine di-p-toluoyl-D-tartrate
  参考文献：
  名称：

  [EN] A PROCESS FOR THE PREPARATION OF TERT-BUTYL (R) - 3 -VINYLPYRROLIDINE- I - CARBOXYLATE AND INTERMEDIATES THEREFOR
  [FR] NOUVEAUX COMPOSÉS

  摘要：

  公开号：

  WO2010065447A3

文献信息

• NOVEL COMPOUNDS
  申请人：Akireddy Srinivasa Rao

  公开号：US20110269975A1

  公开（公告）日：2011-11-03

  The present invention related to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to novel salts thereof, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).

  本发明涉及与神经尼古丁乙酰胆碱受体结合并调节其活性的化合物，其新型盐，制备这些化合物的过程，含有这些化合物的制药组合物以及使用这些化合物治疗各种疾病和疾病的方法，包括与中枢神经系统(CNS)功能障碍相关的疾病和疾病。
• Synthesis and Novel Salt Forms of (R)-3-((E)-pyrrolidin-3-yl)vinyl)-5-tetrahydropyran-4-yloxy)pyridine
  申请人：Akireddy Srinivasa Rao

  公开号：US20120015983A1

  公开（公告）日：2012-01-19

  The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions.

  本发明涉及(R)-3-((E)-2-(吡咯烷-3-基)乙烯基)-5-(四氢吡喃-4-氧基)吡啶及其盐形式，以及用于在制备药物组合物中使用的这些化合物的商业规模生产的过程，以足够的纯度和质量。
• SYNTHESIS AND NOVEL SALT FORMS OF (R)-3-((E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE
  申请人：Targecept, Inc.

  公开号：US20140107163A1

  公开（公告）日：2014-04-17

  The present invention relates to (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine, its salt forms, and to processes for the commercial-scale production of these compounds in sufficient purity and quality for use in pharmaceutical compositions.

  本发明涉及(R)-3-((E)-2-(吡咯烷-3-基)乙烯基)-5-(四氢吡喃-4-氧基)吡啶及其盐形式，以及用于在制备药物组合物中使用的这些化合物的商业规模生产的过程，使其具有足够的纯度和质量。
• Salt forms of (R)-3-(E)-2-(PYRROLIDIN-3-YL)VINYL)-5-(TETRAHYDROPYRAN-4-YLOXY)PYRIDINE AND their USE
  申请人：Targacept, Inc.

  公开号：EP2896619A1

  公开（公告）日：2015-07-22

  The present invention relates to the hemi-galactarate, oxalate and di-p-toluoyl-D-tartrate salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine or hydrates or solvates thereof, compositions comprising these salt and their use for treating or preventing a NNR mediated disorder.

  本发明涉及(R)-3-((E)-2-(吡咯烷-3-基)乙烯基)-5-(四氢吡喃-4-氧基)吡啶或其水合物或溶液的半半乳糖盐、草酸盐和二对甲苯甲酰基-D-酒石酸盐形式、包含这些盐的组合物及其用于治疗或预防 NNR 介导的疾病的用途。
• Novel compounds
  申请人：Targacept Inc.

  公开号：EP2358670A2

  公开（公告）日：2011-08-24